WallStreetZenWallStreetZen

NASDAQ: ADIL
Adial Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their ADIL stock forecasts and price targets.

Forecast return on equity

Is ADIL forecast to generate an efficient return?
Company
N/A
Industry
72.03%
Market
80.59%

Forecast return on assets

Is ADIL forecast to generate an efficient return on assets?
Company
N/A
Industry
30.89%

ADIL earnings per share forecast

What is ADIL's earnings per share in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$1.66

ADIL revenue forecast

What is ADIL's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$46.4M
Avg 2 year Forecast
$93.8M
Avg 3 year Forecast
$142.3M

ADIL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ADIL$1.07N/AN/A
HOTH$0.94$5.50+485.11%Strong Buy
MBIO$0.37$2.00+443.48%Buy
TRVN$0.24$5.00+1,966.12%Buy
MYMD$1.91N/AN/A

Adial Pharmaceuticals Stock Forecast FAQ

What is ADIL's earnings growth forecast for 2024-2024?

(NASDAQ: ADIL) Adial Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.75%.

Adial Pharmaceuticals's earnings in 2024 is -$8,694,065.

In 2024, ADIL is forecast to generate -$7,027,291 in earnings, with the lowest earnings forecast at -$7,027,291 and the highest earnings forecast at -$7,027,291.

If you're new to stock investing, here's how to buy Adial Pharmaceuticals stock.

What is ADIL's revenue growth forecast for 2026-2028?

(NASDAQ: ADIL) Adial Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.3%.

Adial Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ADIL's revenue for 2026 to be $196,340,825, with the lowest ADIL revenue forecast at $196,340,825, and the highest ADIL revenue forecast at $196,340,825. On average, 1 Wall Street analysts forecast ADIL's revenue for 2027 to be $397,168,957, with the lowest ADIL revenue forecast at $397,168,957, and the highest ADIL revenue forecast at $397,168,957.

In 2028, ADIL is forecast to generate $602,442,061 in revenue, with the lowest revenue forecast at $602,442,061 and the highest revenue forecast at $602,442,061.

What is ADIL's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ADIL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 30.89%.

What is ADIL's Earnings Per Share (EPS) forecast for 2024-2024?

(NASDAQ: ADIL) Adial Pharmaceuticals's current Earnings Per Share (EPS) is -$3.15. In 2024, ADIL's EPS is forecast to hit -$1.66 (min: -$1.66, max: -$1.66).

What is ADIL's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ADIL) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.